5-HT2A Agonists - Pipeline Insight, 2022

“5-HT2A Agonists - Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in 5-HT2A Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

5-HT2A Agonists Understanding

5-HT2A Agonists: Overview

The 5-HT2A receptor is a subtype of the 5-HT2 receptor that belongs to the serotonin receptor family and is a G protein-coupled receptor (GPCR). The 5-HT2A receptor is a cell surface receptor. 5-HT is short for 5-hydroxy-tryptamine, which is serotonin.

Function - 5-HT2A is the main excitatory receptor subtype among the GPCRs for serotonin, although 5-HT2A may also have an inhibitory effect on certain areas such as the visual cortex and the orbitofrontal cortex. The 5-HT2A receptor is known primarily to couple to the Gαq signal transduction pathway. Upon receptor stimulation with agonist, Gαq and β-γ subunits dissociate to initiate downstream effector pathways. Gαq stimulates phospholipase C (PLC) activity, which subsequently promotes the release of diacylglycerol (DAG) and inositol triphosphate (IP3), which in turn stimulate protein kinase C (PKC) activity and Ca2+ release

5-HT2A Agonists -. Activation of the 5-HT2A receptor is necessary for the effects of the ""classic"" psychedelics like LSD, psilocin and mescaline, which act as full or partial agonists at this receptor, and represent the three main classes of 5-HT2A Agonists, the ergolines, tryptamines and phenethylamines, respectively. A very large family of derivatives from these three classes has been developed, and their structure-activity relationships have been extensively researched. Agonists acting at 5-HT2A receptors located on the apical dendrites of pyramidal cells within regions of the prefrontal cortex are believed to mediate hallucinogenic activity. Newer findings reveal that psychoactive effects of classic psychedelics are mediated by the receptor heterodimer 5-HT2A–mGlu2 and not by monomeric 5-HT2A receptors. Agonists enhance dopamine in PFC, enhance memory and play an active role in attention and learning.

5-HT2A Agonists Emerging Drugs Chapters

This segment of the 5-HT2A Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

5-HT2A Agonists Emerging Drugs
• Brilaroxazine : Reviva Biopharmaceuticals

Brilaroxazine (formerly known as RP 5063), is an orally bioavailable small molecule therapeutic, as a best-in-class treatment for schizophrenia, schizoaffective disorders, major depressive disorders, bipolar disorders, attention-deficit hyperactivity disorder and other neurological disorders, is being developed by Reviva Biopharmaceuticals. The drug is currently in phase 2 of clinical development for the treatment of Schizoaffective disorder; Schizophrenia.

Further product details are provided in the report……..

5-HT2A Agonists: Therapeutic Assessment

This segment of the report provides insights about the different 5-HT2A Agonists drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on 5-HT2A Agonists

There are approx. 3+ key companies which are developing the 5-HT2A Agonists. The companies which have their 5-HT2A Agonists drug candidates in the most advanced stage, i.e. phase 2 include, Reviva Biopharmaceuticals.
• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

5-HT2A Agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

5-HT2A Agonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses 5-HT2A Agonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging 5-HT2A Agonists drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence 5-HT2A Agonists R&D. The therapies under development are focused on novel approaches for 5-HT2A Agonists.

5-HT2A Agonists Report Insights
• 5-HT2A Agonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

5-HT2A Agonists Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing 5-HT2A Agonists drugs?
• How many 5-HT2A Agonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for 5-HT2A Agonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the 5-HT2A Agonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for 5-HT2A Agonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Reviva Biopharmaceuticals
• CURE Pharmaceutical
• EmpathBio
• Eleusis

Key Products
• Brilaroxazine
• Lysergide
• EMP 01
• ELE 02